Interferon-α in acute myeloid leukemia: an old drug revisited

Leukemia. 2011 May;25(5):739-48. doi: 10.1038/leu.2010.324. Epub 2011 Jan 28.


Interferon-α (IFN-α), a type I IFN, is a well-known antitumoral agent. The investigation of its clinical properties in acute myeloid leukemia (AML) has been prompted by its pleiotropic antiproliferative and immune effects. So far, integration of IFN-α in the therapeutic arsenal against AML has been modest in view of the divergent results of clinical trials. Recent insights into the key pharmacokinetic determinants of the clinical efficacy of IFN along with advances in its pharmaceutical formulation, have sparked renewed interest in its use. This paper reviews the possible applicability of IFN-α in the treatment of AML and provides a rational basis to re-explore its efficacy in clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Interferon-alpha / therapeutic use*
  • Leukemia, Myeloid, Acute / drug therapy*


  • Antineoplastic Agents
  • Interferon-alpha